Richard Neubig

List of Publications by Year
in descending order

265 papers	13,276 citations	22153 59 h-index	30087 103 g-index
416 all docs	416 docs citations	416 times ranked	12013 citing authors

#	Article	IF	Citations
1	Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells. Molecular Pharmacology, 2022, 101, 1-12.	2.3	5
2	Mice with monoallelic GNAO1 loss exhibit reduced inhibitory synaptic input to cerebellar Purkinje cells. Journal of Neurophysiology, 2022, 127, 607-622.	1.8	5
3	BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors. Frontiers in Oncology, 2022, 12, 766794.	2.8	2
4	A Glowing Opportunity to Target YAP in Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 1-2.	2.9	1
5	Mice With Monoallelic GNAO1 Loss Exhibit Reduced Inhibitory Synaptic Input to Cerebellar Purkinje Cells. FASEB Journal, 2022, 36, .	0.5	0
6	Mice with an RGS-insensitive GÎ±i2 protein show growth hormone axis dysfunction. Molecular and Cellular Endocrinology, 2021, 521, 111098.	3.2	3
7	COVID-19â€"A Theory of Autoimmunity Against ACE-2 Explained. Frontiers in Immunology, 2021, 12, 582166.	4.8	41
8	Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell Lines. Cancers, 2021, 13, 2012.	3.7	6
9	Transforming Growth Factor Î²1 Increases Expression of Contractile Genes in Human Pulmonary Arterial Smooth Muscle Cells by Potentiating Sphingosine-1-Phosphate Signaling. Molecular Pharmacology, 2021, 100, 83-90.	2.3	7
10	Convergent olfactory trace amine-associated receptors detect biogenic polyamines with distinct motifs via a conserved binding site. Journal of Biological Chemistry, 2021, 297, 101268.	3.4	6
11	Class A Orphans in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	3
12	G protein-coupled estrogen receptor in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
13	RGS4 negatively modulates Nociceptin/Orphanin FQ opioid receptor signaling: implication for Lâ€Dopaâ€induced dyskinesia.. British Journal of Pharmacology, 2021, , .	5.4	1
14	Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells. Oncogene, 2020, 39, 1466-1483.	5.9	40
15	Two highly related odorant receptors specifically detect Î±-bile acid pheromones in sea lamprey (Petromyzon marinus). Journal of Biological Chemistry, 2020, 295, 12153-12166.	3.4	6
16	Mice with GNAO1 R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, jpet.119.262733.	2.5	14
17	Class A Orphans (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	7
18	Spermine in semen of male sea lamprey acts as a sex pheromone. PLoS Biology, 2019, 17, e3000332.	5.6	37

#	Article	IF	Citations
19	Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay. Scientific Reports, 2019, 9, 10278.	3.3	4
20	RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. Cancer Cell, 2019, 36, 68-83.e9.	16.8	104
21	Mouse models of GNAO1-associated movement disorder: Allele- and sex-specific differences in phenotypes. PLoS ONE, 2019, 14, e0211066.	2.5	18
22	The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice. Scientific Reports, 2019, 9, 7072.	3.3	17
23	Cover Image, Volume 87, Issue 2. Proteins: Structure, Function and Bioinformatics, 2019, 87, C1.	2.6	0
24	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. ACS Pharmacology and Translational Science, 2019, 2, 92-100.	4.9	28
25	5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. Journal of Medicinal Chemistry, 2019, 62, 4350-4369.	6.4	34
26	A Two-Pulse Cellular Stimulation Test Elucidates Variability and Mechanisms in Signaling Pathways. Biophysical Journal, 2019, 116, 962-973.	0.5	11
27	An Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency for Regulators of G-protein Signaling Proteins 4, 8, and 19. Molecular Pharmacology, 2019, 96, 683-691.	2.3	8
28	Loss-of-Function Mutations in Human Regulator of G Protein Signaling RGS2 Differentially Regulate Pharmacological Reactivity of Resistance Vasculature. Molecular Pharmacology, 2019, 96, 826-834.	2.3	6
29	Interplay of cysteine exposure and global protein dynamics in smallâ€molecule recognition by a regulator of Gâ€protein signaling protein. Proteins: Structure, Function and Bioinformatics, 2019, 87, 146-156.	2.6	13
30	Class A Orphans (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	8
31	G protein-coupled estrogen receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	1
32	A Salt Bridge between Î±4 and Î±5 Helices Drives Differences in Flexibility and Potency of Inhibition among Regulator of Gâ€protein Signaling (RGS) Proteins. FASEB Journal, 2019, 33, 784.16.	0.5	0
33	Mice with Gnao1 G203R Gainâ€ofâ€Function (GOF) Mutation Phenocopy Combined Movement Disorder and Seizures of Patients. FASEB Journal, 2019, 33, 667.4.	0.5	0
34	Class A Orphans (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
35	Differential Protein Dynamics of Regulators of G-Protein Signaling: Role in Specificity of Small-Molecule Inhibitors. Journal of the American Chemical Society, 2018, 140, 3454-3460.	13.7	21
36	Role of signalling molecules in behaviours mediated by the Î´ opioid receptor agonist SNC80. British Journal of Pharmacology, 2018, 175, 891-901.	5.4	31

#	Article	IF	Citations
37	In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis. Journal of Nanobiotechnology, 2018, 16, 97.	9.1	20
38	Role of hippocampal 5-HT1A receptors in the antidepressant-like phenotype of mice expressing RGS-insensitive Gİ±i2 protein. Neuropharmacology, 2018, 141, 296-304.	4.1	2
39	Interpreting Hydrogenâ€“Deuterium Exchange Events in Proteins Using Atomistic Simulations: Case Studies on Regulators of G-Protein Signaling Proteins. Journal of Physical Chemistry B, 2018, 122, 9314-9323.	2.6	30
40	A mechanistic review on GNAO1-associated movement disorder. Neurobiology of Disease, 2018, 116, 131-141.	4.4	62
41	Novel antifibrotic target related to RhoA-induced MRTF activation in fibrotic diseases. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY84-4.	0.0	0
42	Loss of function RGS2 mutations augment vascular contractility ex vivo. FASEB Journal, 2018, 32, 699.2.	0.5	0
43	Role of Protein Dynamics in Selectivity of Thiadiazolidinone Inhibition of RGS Proteins. FASEB Journal, 2018, 32, 557.9.	0.5	0
44	Chemerin-induced arterial contraction is Gi- and calcium-dependent. Vascular Pharmacology, 2017, 88, 30-41.	2.1	33
45	Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1744-1749.	2.2	42
46	Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis. Scientific Reports, 2017, 7, 518.	3.3	52
47	The DRY motif and the four corners of the cubic ternary complex model. Cellular Signalling, 2017, 35, 16-23.	3.6	14
48	Regulator of G Protein Signaling 6 Protects the Heart from Ischemic Injury. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 409-416.	2.5	15
49	Human Missense Mutations in Regulator of G Protein Signaling 2 Affect the Protein Function Through Multiple Mechanisms. Molecular Pharmacology, 2017, 92, 451-458.	2.3	12
50	Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations. Neurology, 2017, 89, 762-770.	1.1	73
51	The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors. Psychopharmacology, 2017, 234, 29-39.	3.1	19
52	Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma. Molecular Cancer Therapeutics, 2017, 16, 193-204.	4.1	35
53	A central role for R7bp in the regulation of itch sensation. Pain, 2017, 158, 931-944.	4.2	11
54	Investigating Regulator of Gâ€protein Signaling (RGS) Protein Dynamics by Hydrogen/Deuterium Exchange. FASEB Journal, 2017, 31, 665.8.	0.5	0

#	Article	IF	Citations
55	Small-Molecule Inhibition of Rho/MKL/SRF Transcription in Prostate Cancer Cells: Modulation of Cell Cycle, ER Stress, and Metastasis Gene Networks. Microarrays (Basel, Switzerland), 2016, 5, 13.	1.4	21
56	Optimisation of Intestinal Fibrosis and Survival in the MouseS. TyphimuriumModel for Anti-fibrotic Drug Discovery and Preclinical Applications. Journal of Crohn's and Colitis, 2016, 11, jjw210.	1.3	6
57	RGS Proteins and GÎ±i2 Modulate Sleep, Wakefulness, and Disruption of Sleep/ Wake States after Isoflurane and Sevoflurane Anesthesia. Sleep, 2016, 39, 393-404.	1.1	7
58	Digoxin-Mediated Upregulation of RGS2 Protein Protects against Cardiac Injury. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 311-319.	2.5	20
59	FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex. PLoS ONE, 2015, 10, e0123581.	2.5	21
60	Band-pass processing in a GPCR signaling pathway selects for NFAT transcription factor activation. Integrative Biology (United Kingdom), 2015, 7, 1378-1386.	1.3	20
61	Inhibition of Myocardin-Related Transcription Factor/Serum Response Factor Signaling Decreases Lung Fibrosis and Promotes Mesenchymal Cell Apoptosis. American Journal of Pathology, 2015, 185, 969-986.	3.8	138
62	Selectivity and Anti-Parkinsonâ€™s Potential of Thiadiazolidinone RGS4 Inhibitors. ACS Chemical Neuroscience, 2015, 6, 911-919.	3.5	41
63	RGS-Insensitive G Proteins as In Vivo Probes of RGS Function. Progress in Molecular Biology and Translational Science, 2015, 133, 13-30.	1.7	20
64	M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron, 2015, 88, 762-773.	8.1	183
65	Regulator of G Protein Signaling Protein 6 (RGS6) Protects the Heart from Ischemic Injury. FASEB Journal, 2015, 29, 1026.8.	0.5	0
66	RGS4 Differentially Regulates Antidepressant and Locomotor Behaviors In Vivo. FASEB Journal, 2015, 29, 618.11.	0.5	0
67	RGS2 Protein Degradation is Mediated by a Novel Cullin 4B/Fâ€box 44 E3 Ligase Complex. FASEB Journal, 2015, 29, 618.15.	0.5	0
68	Regulation of Protease-activated Receptor 1 Signaling by the Adaptor Protein Complex 2 and R4 Subfamily of Regulator of G Protein Signaling Proteins. Journal of Biological Chemistry, 2014, 289, 1580-1591.	3.4	13
69	Identification of Protein Kinase C Activation as a Novel Mechanism for RGS2 Protein Upregulation through Phenotypic Screening of Natural Product Extracts. Molecular Pharmacology, 2014, 86, 406-416.	2.3	15
70	Novel Rho/MRTF/SRF Inhibitors Block Matrix-stiffness and TGF-Î²â€“Induced Fibrogenesis in Human Colonic Myofibroblasts. Inflammatory Bowel Diseases, 2014, 20, 154-165.	1.9	155
71	Targeting the Myofibroblast Genetic Switch: Inhibitors of Myocardin-Related Transcription Factor/Serum Response Factorâ€“Regulated Gene Transcription Prevent Fibrosis in a Murine Model of Skin Injury. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 480-486.	2.5	92
72	Redox Modification of Nuclear Actin by MICAL-2 Regulates SRF Signaling. Cell, 2014, 156, 563-576.	28.9	142

#	Article	IF	Citations
73	Cellular Mechanisms of Tissue Fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. American Journal of Physiology - Cell Physiology, 2014, 307, C2-C13.	4.6	71
74	Induction of the matricellular protein CCN1 through RhoA and MRTF-A contributes to ischemic cardioprotection. Journal of Molecular and Cellular Cardiology, 2014, 75, 152-161.	1.9	29
75	Gain-of-function mutation in Gnao1: A murine model of epileptiform encephalopathy (EIEE17)?. Mammalian Genome, 2014, 25, 202-210.	2.2	34
76	International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands. Pharmacological Reviews, 2014, 66, 918-947.	16.0	189
77	Conditional disruption of interactions between GÎ±i2 and regulator of G protein signaling (RGS) proteins protects the heart from ischemic injury. BMC Pharmacology & Toxicology, 2014, 15, 29.	2.4	9
78	Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3826-3832.	2.2	61
79	Conformational Dynamics of a Regulator of G-Protein Signaling Protein Reveals a Mechanism of Allosteric Inhibition by a Small Molecule. ACS Chemical Biology, 2013, 8, 2778-2784.	3.4	33
80	NMR Methods for Detection of Small Molecule Binding to RGS4. Methods in Enzymology, 2013, 522, 133-152.	1.0	5
81	Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay. Cellular Signalling, 2013, 25, 2848-2855.	3.6	21
82	Microfluidic interrogation and mathematical modeling of multi-regime calcium signaling dynamics. Integrative Biology (United Kingdom), 2013, 5, 932.	1.3	11
83	Regulation of G protein signaling by the 70kDa heat shock protein. Cellular Signalling, 2013, 25, 389-396.	3.6	8
84	Differential Control of Opioid Antinociception to Thermal Stimuli in a Knock-In Mouse Expressing Regulator of G-Protein Signaling-Insensitive GÎ±_oProtein. Journal of Neuroscience, 2013, 33, 4369-4377.	3.6	29
85	International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands. Pharmacological Reviews, 2013, 65, 967-986.	16.0	250
86	Detection of G Protein-selective G Protein-coupled Receptor (GPCR) Conformations in Live Cells. Journal of Biological Chemistry, 2013, 288, 17167-17178.	3.4	60
87	Design and synthesis of tag-free photoprobes for the identification of the molecular target for CCG-1423, a novel inhibitor of the Rho/MKL1/SRF signaling pathway. Beilstein Journal of Organic Chemistry, 2013, 9, 966-973.	2.2	22
88	RGS 2 and RGS 4 Differentially Modulate G Protein Coupled Receptor Signaling in the Mouse Aorta. FASEB Journal, 2013, 27, 1095.3.	0.5	0
89	Dynamic control of Allosteric Inhibitor Specificity for RGS4. FASEB Journal, 2013, 27, 1095.11.	0.5	0
90	Increased Go activity in C57Bl/6J mice enhances sensitivity to a model of epilepsy. FASEB Journal, 2013, 27, 660.1.	0.5	0

#	Article	IF	Citations
91	Cardiotonic Steroids Stabilize Regulator of G Protein Signaling 2 Protein Levels. Molecular Pharmacology, 2012, 82, 500-509.	2.3	23
92	MScreen: An Integrated Compound Management and High-Throughput Screening Data Storage and Analysis System. Journal of Biomolecular Screening, 2012, 17, 1080-1087.	2.6	44
93	The Loss of RGS Protein-GÎ±_{i2} Interactions Results in Markedly Impaired Mouse Neutrophil Trafficking to Inflammatory Sites. Molecular and Cellular Biology, 2012, 32, 4561-4571.	2.3	32
94	A newly identified complex of spinophilin and the tyrosine phosphatase, SHP-1, modulates platelet activation by regulating G proteinâ€“dependent signaling. Blood, 2012, 119, 1935-1945.	1.4	57
95	Toll-like Receptor-Induced Inflammatory Cytokines are Suppressed by Gain of Function or Overexpression of GÎ± i2 Protein. Inflammation, 2012, 35, 1611-1617.	3.8	16
96	GÎ±i2 signaling: friend or foe in cardiac injury and heart failure?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 443-453.	3.0	15
97	Small Molecule Inhibitors of Regulators of G Protein Signaling (RGS) Proteins. ACS Medicinal Chemistry Letters, 2012, 3, 146-150.	2.8	41
98	Increased CD39 Nucleotidase Activity on Microparticles from Patients with Idiopathic Pulmonary Arterial Hypertension. PLoS ONE, 2012, 7, e40829.	2.5	43
99	Targeting degradation pathways of RGS2 using highâ€throughput siRNA screening. FASEB Journal, 2012, 26, 838.9.	0.5	0
100	S1P induces CCN1 expression through RhoA/MRTFâ€a activation and protects cardiomyocytes against cell death. FASEB Journal, 2012, 26, 1060.4.	0.5	0
101	Generation of GÎ± i2 G184S conditional mutant mice to study regulator of G protein signaling (RGS) proteins. FASEB Journal, 2012, 26, 1114.10.	0.5	0
102	Hi-Fi transmission of periodic signals amid cell-to-cell variability. Molecular BioSystems, 2011, 7, 2238.	2.9	16
103	A Nanomolar-Potency Small Molecule Inhibitor of Regulator of G-Protein Signaling Proteins. Biochemistry, 2011, 50, 3181-3192.	2.5	55
104	RGS-Insensitive GÎ± Subunits: Probes of GÎ± Subtype-Selective Signaling and Physiological Functions of RGS Proteins. Methods in Molecular Biology, 2011, 756, 75-98.	0.9	14
105	Complementary Cell-Based High-Throughput Screens Identify Novel Modulators of the Unfolded Protein Response. Journal of Biomolecular Screening, 2011, 16, 825-835.	2.6	44
106	GÎ±i2-mediated protection from ischaemic injury is modulated by endogenous RGS proteins in the mouse heart. Cardiovascular Research, 2011, 91, 45-52.	3.8	17
107	Glossary of terms used in biomolecular screening (IUPAC Recommendations 2011). Pure and Applied Chemistry, 2011, 83, 1129-1158.	1.9	8
108	Differential effects of Go and Gi2 on seizure threshold. FASEB Journal, 2011, 25, 1010.2.	0.5	0

#	Article	IF	Citations
109	RGS/Gi2Î± interactions modulate platelet accumulation and thrombus formation at sites of vascular injury. Blood, 2010, 116, 6092-6100.	1.4	52
110	Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 665-672.	2.2	60
111	GÎ± Subunit Coordinates with Ephrin-B to Balance Self-Renewal and Differentiation in Neural Progenitor Cells. Stem Cells, 2010, 28, 1581-1589.	3.2	17
112	Differential modulation of muâ€opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is GÎ± subtype dependent. Journal of Neurochemistry, 2010, 112, 1026-1034.	3.9	29
113	Mind Your Salts: When the Inactive Constituent Isn't: Fig. 1.. Molecular Pharmacology, 2010, 78, 558-559.	2.3	18
114	Reversible, Allosteric Small-Molecule Inhibitors of Regulator of G Protein Signaling Proteins. Molecular Pharmacology, 2010, 78, 524-533.	2.3	70
115	Allosteric Inhibition of the Regulator of G Protein Signalingâ€“Gα Proteinâ€“Protein Interaction by CCG-4986. Molecular Pharmacology, 2010, 78, 360-365.	2.3	39
116	GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics, 2010, 26, 1804-1805.	4.1	74
117	RGS inhibition at Gα _{i2} selectively potentiates 5-HT1Aâ€“mediated antidepressant effects. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11086-11091.	7.1	60
118	Phase-Locked Signals Elucidate Circuit Architecture of an Oscillatory Pathway. PLoS Computational Biology, 2010, 6, e1001040.	3.2	40
119	Regulators of G Protein Signaling Proteins as Targets for Drug Discovery. Progress in Molecular Biology and Translational Science, 2010, 91, 81-119.	1.7	84
120	Analyzing Binding Data. Current Protocols in Neuroscience, 2010, 52, Unit 7.5.	2.6	41
121	Thinking Outside of the â€œRGS Boxâ€: New Approaches to Therapeutic Targeting of Regulators of G Protein Signaling: Fig. 1.. Molecular Pharmacology, 2010, 78, 550-557.	2.3	67
122	Use of Flow Cytometric Methods to Quantify Proteinâ€Protein Interactions. Current Protocols in Cytometry, 2010, 51, Unit 13.11.1-15.	3.7	27
123	RGS7 Protein Suppression of Gαo Proteinâ€Mediated Î±2Aâ€Adrenergic Receptor Inhibition of Mouse Hippocampal CA3 Epileptiform Activity. FASEB Journal, 2010, 24, 587.3.	0.5	0
124	International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature. Pharmacological Reviews, 2009, 61, 1-8.	16.0	49
125	Polyplexed Flow Cytometry Protein Interaction Assay: A Novel High-Throughput Screening Paradigm for RGS Protein Inhibitors. Journal of Biomolecular Screening, 2009, 14, 610-619.	2.6	38
126	Regulator of G Protein Signaling Protein Suppression of Gα_o Protein-Mediated Î±_{2A} Adrenergic Receptor Inhibition of Mouse Hippocampal CA3 Epileptiform Activity. Molecular Pharmacology, 2009, 75, 1222-1230.	2.3	26

#	Article	IF	Citations
127	High-Throughput Screening for Small-Molecule Inhibitors of LARG-Stimulated RhoA Nucleotide Binding via a Novel Fluorescence Polarization Assay. Journal of Biomolecular Screening, 2009, 14, 161-172.	2.6	42
128	IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Research, 2009, 37, D680-D685.	14.5	199
129	A Juxtamembrane Mutation in the N Terminus of the Dopamine Transporter Induces Preference for an Inward-Facing Conformation. Molecular Pharmacology, 2009, 75, 514-524.	2.3	61
130	A conserved hydrophobic surface of the LARG pleckstrin homology domain is critical for RhoA activation in cells. Cellular Signalling, 2009, 21, 1569-1578.	3.6	22
131	A covalent peptide inhibitor of RGS4 identified in a focused one-bead, one compound library screen. BMC Pharmacology, 2009, 9, 9.	0.4	18
132	GNAI2 and regulators of G protein signaling as a potential Noonan syndrome mechanism. Medical Hypotheses, 2009, 73, 56-59.	1.5	4
133	Small Molecule Proteinâ€“Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles. Neuropsychopharmacology, 2009, 34, 126-141.	5.4	164
134	Isoflurane-Induced Changes in Righting Response and Breathing Are Modulated by RGS Proteins. Anesthesia and Analgesia, 2009, 109, 1500-1505.	2.2	16
135	Functional Selectivity at Adrenergic Receptors. , 2009, , 107-124.		0
136	In vitro protein kinase activity measurement by flow cytometry. Analytical Biochemistry, 2008, 383, 180-185.	2.4	7
137	Novel Peptide Ligands of RGS4 from a Focused Oneâ€Bead, Oneâ€Compound Library. Chemical Biology and Drug Design, 2008, 72, 111-119.	3.2	25
138	Microfabricated Channel Array Electrophoresis for Characterization and Screening of Enzymes Using RGSâ^'G Protein Interactions as a Model System. Analytical Chemistry, 2008, 80, 5225-5231.	6.5	18
139	And the Winner Is â€¦ RGS4!. Circulation Research, 2008, 103, 444-446.	4.5	8
140	Assembly of High Order GÎ±q-Effector Complexes with RGS Proteins. Journal of Biological Chemistry, 2008, 283, 34923-34934.	3.4	46
141	Resistance to Diet-Induced Obesity and Improved Insulin Sensitivity in Mice With a Regulator of G Protein Signalingâ€“Insensitive G184S Gnai2 Allele. Diabetes, 2008, 57, 77-85.	0.6	50
142	Î±2A adrenergic receptor mediated antiepileptic effects via GÎ±o proteins. FASEB Journal, 2008, 22, 729.3.	0.5	0
143	Genetic deletion of Regulators of G protein Signaling (RGS) protein activity enhances buprenorphine antinociception while limiting withdrawal behaviors associated with chronic administration. FASEB Journal, 2008, 22, 907.7.	0.5	0
144	Mice lacking RGS protein activity at GÎ±i2 exhibit a 5HT1A receptorâ€mediated antidepressantâ€like phenotype. FASEB Journal, 2008, 22, 907.8.	0.5	0

#	Article	IF	Citations
145	High Throughtput Screening Using A Polyplexed Flow Cytometry Protein Interaction Assay (FCPIA) for Small Molecule Inhibitors of Regulator of G protein Signaling (RGS) Proteins. FASEB Journal, 2008, 22, 907.2.	0.5	0
146	Missing Links: Mechanisms of Protean Agonism: Fig. 1.. Molecular Pharmacology, 2007, 71, 1200-1202.	2.3	24
147	International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers. Pharmacological Reviews, 2007, 59, 5-13.	16.0	274
148	N-Terminal Residues Control Proteasomal Degradation of RGS2, RGS4, and RGS5 in Human Embryonic Kidney 293 Cells. Molecular Pharmacology, 2007, 71, 1040-1050.	2.3	84
149	Structure of GÎ± _q -p63RhoGEF-RhoA Complex Reveals a Pathway for the Activation of RhoA by GPCRs. Science, 2007, 318, 1923-1927.	12.6	206
150	Endogenous RGS proteins modulate SA and AV nodal functions in isolated heart: implications for sick sinus syndrome and AV block. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H2532-H2539.	3.2	40
151	Fluorescence-Based Adenylyl Cyclase Assay Adaptable to High Throughput Screening. Combinatorial Chemistry and High Throughput Screening, 2007, 10, 289-298.	1.1	5
152	CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Molecular Cancer Therapeutics, 2007, 6, 2249-2260.	4.1	189
153	The Highly Conserved DRY Motif of Class A G Protein-Coupled Receptors: Beyond the Ground State. Molecular Pharmacology, 2007, 71, 959-964.	2.3	322
154	Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction Assay. Molecular Pharmacology, 2007, 71, 169-175.	2.3	123
155	Capillary Electrophoresis Assay for G Protein-Coupled Receptor-Mediated GTPase Activity. Analytical Chemistry, 2007, 79, 1158-1163.	6.5	5
156	Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature, 2007, 449, 721-725.	27.8	396
157	Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics, 2007, 8, 177.	2.6	42
158	Characterization and mechanistic investigation of CCGâ€4986, a small molecule RGS4 inhibitor. FASEB Journal, 2007, 21, A431.	0.5	1
159	Development of a Time Resolved FRET Highâ€Throughput Assay to Identify Inhibitors of the RGS4/GÎ±o Interaction. FASEB Journal, 2007, 21, A431.	0.5	1
160	Peptide ligands of Regulators of Gâ€Protein Signaling 4 (RGS4) identified by screening of a focused oneâ€bead, oneâ€compound peptide library. FASEB Journal, 2007, 21, A1002.	0.5	1
161	Biphasic regulation of muâ€opioid signaling to adenylyl cyclase by GTPase accelerating protein (GAP) activity of RGS7. FASEB Journal, 2007, 21, A430.	0.5	0
162	Mechanism of Action and Structural Requirements of Constrained Peptide Inhibitors of RGS Proteins. Chemical Biology and Drug Design, 2006, 67, 266-274.	3.2	27

#	Article	IF	Citations
163	Endogenous RGS Proteins and GÎ± Subtypes Differentially Control Muscarinic and Adenosine-Mediated Chronotropic Effects. Circulation Research, 2006, 98, 659-666.	4.5	83
164	Regions in the G Protein Î³ Subunit Important for Interaction with Receptors and Effectors. Molecular Pharmacology, 2006, 69, 877-887.	2.3	27
165	Pleiotropic Phenotype of a Genomic Knock-In of an RGS-Insensitive G184S Gnai2 Allele. Molecular and Cellular Biology, 2006, 26, 6870-6879.	2.3	75
166	Targeting regulators of G protein signaling (RGS proteins) to enhance agonist specificity. , 2006, , 93-103.		1
167	International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List. Pharmacological Reviews, 2005, 57, 279-288.	16.0	452
168	International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function. Pharmacological Reviews, 2005, 57, 541-546.	16.0	215
169	Galanin Receptor 1 Has Anti-proliferative Effects in Oral Squamous Cell Carcinoma. Journal of Biological Chemistry, 2005, 280, 22564-22571.	3.4	51
170	Real-time Detection of Basal and Stimulated G Protein GTPase Activity Using Fluorescent GTP Analogues. Journal of Biological Chemistry, 2005, 280, 7712-7719.	3.4	41
171	Receptorâ^'Antagonist Interactions in the Complexes of Agouti and Agouti-Related Protein with Human Melanocortin 1 and 4 Receptorsâ€,â€¡. Biochemistry, 2005, 44, 3418-3431.	2.5	47
172	REGULATORs OF G PROTEIN SIGNALING & DRUGS OF ABUSE. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2005, 5, 30-41.	3.4	86
173	RGS-Insensitive G-Protein Mutations to Study the Role of Endogenous RGS Proteins. Methods in Enzymology, 2004, 389, 229-243.	1.0	51
174	Ribozyme- and siRNA-Mediated Suppression of RGS-Containing RhoGEF Proteins. Methods in Enzymology, 2004, 389, 244-265.	1.0	11
175	Real-time Analysis of Ternary Complex on Particles. Journal of Biological Chemistry, 2004, 279, 13514-13521.	3.4	28
176	Endogenous Regulator of G Protein Signaling Proteins Suppress GÎ±o-Dependent, Î¼-Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 215-222.	2.5	37
177	Thrombin and Lysophosphatidic Acid Receptors Utilize Distinct rhoGEFs in Prostate Cancer Cells. Journal of Biological Chemistry, 2004, 279, 28831-28834.	3.4	65
178	Affinity Assays Using Fluorescence Anisotropy with Capillary Electrophoresis Separation. Analytical Chemistry, 2004, 76, 7380-7386.	6.5	17
179	Structure-Based Design, Synthesis, and Activity of Peptide Inhibitors of RGS4 GAP Activity. Methods in Enzymology, 2004, 389, 266-277.	1.0	10
180	Structureâ€based design, synthesis, and pharmacologic evaluation tf peptide RGS4 inhibitors. Chemical Biology and Drug Design, 2004, 63, 141-146.	1.1	32

#	Article	IF	Citations
181	Diabetic neuropathy: inhibitory G protein dysfunction involves PKC-dependent phosphorylation of GoÎ±. Journal of Neurochemistry, 2003, 86, 1006-1014.	3.9	17
182	Ligand-Receptor-G-Protein Molecular Assemblies on Beads for Mechanistic Studies and Screening by Flow Cytometry. Molecular Pharmacology, 2003, 64, 1227-1238.	2.3	35
183	International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology. Pharmacological Reviews, 2003, 55, 597-606.	16.0	536
184	Detection of G Proteins by Affinity Probe Capillary Electrophoresis Using a Fluorescently Labeled GTP Analogue. Analytical Chemistry, 2003, 75, 4297-4304.	6.5	36
185	Depicting a protein's two faces: GPCR classification by phylogenetic tree-based HMMs. FEBS Letters, 2003, 554, 95-99.	2.8	32
186	Inverse agonist activity of agouti and agouti-related protein. Peptides, 2003, 24, 603-609.	2.4	77
187	Endogenous RGS Protein Action Modulates Î¼-Opioid Signaling through GÎ±o. Journal of Biological Chemistry, 2003, 278, 9418-9425.	3.4	92
188	Stimulation of Cellular Signaling and G Protein Subunit Dissociation by G Protein Î²Î³ Subunit-binding Peptides. Journal of Biological Chemistry, 2003, 278, 19634-19641.	3.4	64
189	A Spatial Focusing Model for G Protein Signals. Journal of Biological Chemistry, 2003, 278, 7278-7284.	3.4	121
190	AT1 Receptor Mutant Lacking Heterotrimeric G Protein Coupling Activates the Src-Ras-ERK Pathway without Nuclear Translocation of ERKs. Journal of Biological Chemistry, 2002, 277, 9268-9277.	3.4	131
191	Receptor-selective Effects of Endogenous RGS3 and RGS5 to Regulate Mitogen-activated Protein Kinase Activation in Rat Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2002, 277, 24949-24958.	3.4	115
192	Fluorescence Approaches to Study G Protein Mechanisms. Methods in Enzymology, 2002, 344, 403-420.	1.0	21
193	Fluorescence Analysis of Receptorâ^'G Protein Interactions in Cell Membranesâ€. Biochemistry, 2002, 41, 12858-12867.	2.5	31
194	NMR Structure of the Second Intracellular Loop of the Î±2A Adrenergic Receptor:Â Evidence for a Novel Cytoplasmic Helixâ€,â€¡. Biochemistry, 2002, 41, 3596-3604.	2.5	42
195	Mutagenesis and peptide analysis of the DRY motif in the Î±2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors. Biochemical and Biophysical Research Communications, 2002, 293, 1233-1241.	2.1	52
196	Expression of novel splice variants of the G protein subunit, G o Î±, is tissue-specific and age-dependent in the rat. Gene, 2002, 296, 249-255.	2.2	4
197	Regulators of Gâ€ƒprotein signaling (RGS proteins): Novel central nervous system drug targets. Chemical Biology and Drug Design, 2002, 60, 312-316.	1.1	36
198	Coupling Efficacy and Selectivity of the Human Î¼-Opioid Receptor Expressed as Receptor-GÎ± Fusion Proteins in Escherichia coli. Journal of Neurochemistry, 2002, 75, 1190-1199.	3.9	27

#	Article	IF	Citations
199	Regulators of G-Protein signalling as new central nervous system drug targets. Nature Reviews Drug Discovery, 2002, 1, 187-197.	46.4	351
200	Receptorâ^'G Protein Î³ Specificity:Â Î³11 Shows Unique Potency for A1Adenosine and 5-HT1AReceptorsâ€. Biochemistry, 2001, 40, 10532-10541.	2.5	51
201	ANG II type 1 receptor downregulation does not require receptor endocytosis or G protein coupling. American Journal of Physiology - Cell Physiology, 2001, 281, C801-C809.	4.6	17
202	Inverse Agonist Activity at the Î±_{2A}-Adrenergic Receptor. Molecular Pharmacology, 2001, 59, 532-542.	2.3	51
203	Selective inactivation of guanine-nucleotide-binding regulatory protein (G-protein) Î± and Î²Î³ subunits by urea. Biochemical Journal, 2001, 354, 337.	3.7	14
204	Selective inactivation of guanine-nucleotide-binding regulatory protein (G-protein) Î± and Î²Î³ subunits by urea. Biochemical Journal, 2001, 354, 337-344.	3.7	23
205	Fluorescent BODIPY-GTP Analogs: Real-Time Measurement of Nucleotide Binding to G Proteins. Analytical Biochemistry, 2001, 291, 109-117.	2.4	130
206	Molecular Cloning and Characterization of a Novel Regulator of G-protein Signaling from Mouse Hematopoietic Stem Cells. Journal of Biological Chemistry, 2001, 276, 915-923.	3.4	51
207	Walker A Lysine Mutations of TAP1 and TAP2 Interfere with Peptide Translocation but Not Peptide Binding. Journal of Biological Chemistry, 2001, 276, 7526-7533.	3.4	65
208	Real-time Analysis of G Protein-coupled Receptor Reconstitution in a Solubilized System. Journal of Biological Chemistry, 2001, 276, 22453-22460.	3.4	31
209	USING EVOLUTIONARY METHODS TO STUDY G-PROTEIN COUPLED RECEPTORS. , 2001, , .		1
210	Regulator of G protein signaling proteins: novel multifunctional drug targets. Journal of Pharmacology and Experimental Therapeutics, 2001, 297, 837-45.	2.5	156
211	Rapid Kinetics of Regulator of G-protein Signaling (RGS)-mediated GÎ±i and GÎ±o Deactivation. Journal of Biological Chemistry, 2000, 275, 33497-33503.	3.4	83
212	Timing is everything. Life Sciences, 2000, 68, 647-658.	4.3	51
213	Analysis of Guanine Nucleotide Binding and Exchange Kinetics of the Escherichia coli GTPase Era. Journal of Bacteriology, 2000, 182, 3460-3466.	2.2	37
214	Agonist-directed trafficking of porcine alpha(2A)-adrenergic receptor signaling in Chinese hamster ovary cells: l-isoproterenol selectively activates G(s). Journal of Pharmacology and Experimental Therapeutics, 2000, 294, 539-47.	2.5	50
215	G_iActivator Region of Î±_{2A}-Adrenergic Receptors: Distinct Basic Residues Mediate G_iversus G_sActivation. Molecular Pharmacology, 1999, 56, 1005-1013.	2.3	66
216	Interdomain Interactions Regulate GDP Release from Heterotrimeric G Proteins. Biochemistry, 1999, 38, 13795-13800.	2.5	40

#	Article	IF	Citations
217	Specificity of Receptorâ€“G Protein Coupling: Protein Structure and Cellular Determinants. Seminars in Neuroscience, 1998, 9, 189-197.	2.2	13
218	Roles of GoÎ±Tryptophans in GTP Hydrolysis, GDP Release, and Fluorescence Signalsâ€. Biochemistry, 1998, 37, 837-843.	2.5	24
219	Determinants of Gi1Î± and Î²Î³ Binding. Journal of Biological Chemistry, 1998, 273, 7934-7940.	3.4	71
220	A Point Mutation in GÎ±o and GÎ±i1Blocks Interaction with Regulator of G Protein Signaling Proteins. Journal of Biological Chemistry, 1998, 273, 12794-12797.	3.4	152
221	Cotransfection of second and third intracellular loop fragments inhibit angiotensin AT1a receptor activation of phospholipase C in HEK-293 cells. Journal of Pharmacology and Experimental Therapeutics, 1998, 285, 216-22.	2.5	16
222	Novel form of crosstalk between G protein and tyrosine kinase pathways. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 5417-5421.	7.1	93
223	Partial G Protein Activation by Fluorescent Guanine Nucleotide Analogs. Journal of Biological Chemistry, 1996, 271, 4791-4797.	3.4	32
224	Receptor and Membrane Interaction Sites on GÎ². Journal of Biological Chemistry, 1996, 271, 3336-3339.	3.4	92
225	Structural requirements for G(o) activation by receptor-derived peptides: activation and modulation domains of the alpha 2-adrenergic receptor i3c region. Molecular Pharmacology, 1996, 50, 351-8.	2.3	34
226	Lack of association of G-protein Î²2- and Î³2-subunit N-terminal fragments provides evidence against the coiled-coil model of subunit-Î²Î³ assembly. Biochemical Journal, 1995, 309, 377-380.	3.7	9
227	Effect of Circulating Epinephrine on Platelet Function and Hematocrit. Hypertension, 1995, 25, 1096-1105.	2.7	39
228	Membrane organization in Gâ€protein mechanisms. FASEB Journal, 1994, 8, 939-946.	0.5	344
229	Peptides as probes for G protein signal transduction. Cellular Signalling, 1994, 6, 841-849.	3.6	39
230	Lateral mobility of tetramethylrhodamine (TMR) labelled G protein Î± and Î²Î³ subunits in NG 108-15 cells. Cellular Signalling, 1994, 6, 663-679.	3.6	32
231	Coupling an receptor peptide to G-protein: A new photolabeling agent. Peptides, 1994, 15, 829-834.	2.4	9
232	Rapid kinetics of G protein subunit association: A rate-limiting conformational change?. FEBS Letters, 1994, 355, 251-253.	2.8	21
233	Binding of an alpha 2 adrenergic receptor third intracellular loop peptide to G beta and the amino terminus of G alpha.. Journal of Biological Chemistry, 1994, 269, 27618-27624.	3.4	91
234	Binding of an alpha 2 adrenergic receptor third intracellular loop peptide to G beta and the amino terminus of G alpha. Journal of Biological Chemistry, 1994, 269, 27618-24.	3.4	79

#	Article	IF	Citations
235	The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. Journal of Pharmacology and Experimental Therapeutics, 1994, 271, 1558-65.	2.5	81
236	Multisite interactions of receptors and G proteins: enhanced potency of dimeric receptor peptides in modifying G protein function. Molecular Pharmacology, 1994, 45, 1191-7.	2.3	23
237	Fluorescent guanine nucleotide analogs and G protein activation. Journal of Biological Chemistry, 1994, 269, 13771-8.	3.4	47
238	Modern NMR spectroscopy of proteins and peptides in solution and its relevance to drug design. Journal of Computer - Aided Molecular Design, 1993, 1, 391-417.	1.0	4
239	Resonance energy transfer between guanine nucleotide binding protein subunits and membrane lipids. Biochemistry, 1993, 32, 2409-2414.	2.5	12
240	Synthesis and characterization of fluorescently labeled bovine brain G protein subunits. Biochemistry, 1993, 32, 2401-2408.	2.5	19
241	Compartmentation of receptors and guanine nucleotide-binding proteins in NG108-15 cells: lack of cross-talk in agonist binding among the alpha 2-adrenergic, muscarinic, and opiate receptors. Molecular Pharmacology, 1993, 43, 434-43.	2.3	52
242	Subsecond modulation of formyl peptide-linked guanine nucleotide-binding proteins by guanosine 5'-O-(3-thio)triphosphate in permeabilized neutrophils. Molecular Pharmacology, 1993, 43, 734-40.	2.3	13
243	A threshold level of coupled G-proteins is required to transduce neutrophil responses. Journal of Immunology, 1992, 149, 2172-8.	0.8	13
244	Two peptides from the alpha 2A-adrenergic receptor alter receptor G protein coupling by distinct mechanisms. Journal of Biological Chemistry, 1991, 266, 11025-9.	3.4	70
245	Multiple Gi protein subtypes regulate a single effector mechanism. Molecular Pharmacology, 1991, 40, 707-11.	2.3	61
246	Subcellular distribution of Î±2-adrenergic receptors, pertussis-toxin substrate and adenylate cyclase in human platelets. Biochemical Journal, 1990, 265, 755-762.	3.7	5
247	Sensitization of human Î±1- and Î±2-adrenergic venous responses by guanadrel sulfate. Clinical Pharmacology and Therapeutics, 1990, 48, 537-543.	4.7	16
248	p-[125I]iodoclonidine is a partial agonist at the alpha 2-adrenergic receptor. Molecular Pharmacology, 1990, 38, 214-21.	2.3	19
249	Nonadrenergic [3H]idazoxan binding sites are physically distinct from alpha 2-adrenergic receptors. Molecular Pharmacology, 1990, 37, 65-8.	2.3	55
250	How does a key fit a flexible lock? Structure and dynamics in receptor function. BioEssays, 1989, 11, 136-141.	2.5	14
251	Rapid kinetics of .alpha.2-adrenergic inhibition of adenylate cyclase. Evidence for a distal rate-limiting step. Biochemistry, 1989, 28, 8778-8786.	2.5	32
252	The hypertension???coronary heart disease dilemma: the catecholamine???blood platelet connection. Journal of Hypertension, 1989, 7, 851-860.	0.5	23

#	Article	IF	Citations
253	Mechanism of agonist and antagonist binding to .alpha.2 adrenergic receptors: evidence for a precoupled receptor-guanine nucleotide protein complex. Biochemistry, 1988, 27, 2374-2384.	2.5	101
254	Temperature effects on Î±2-adrenergic receptor-Gi interactions. Biochemical Pharmacology, 1988, 37, 2815-2821.	4.4	13
255	Inhibition of adenylate cyclase is mediated by the high affinity conformation of the alpha 2-adrenergic receptor. Molecular Pharmacology, 1988, 34, 814-22.	2.3	40
256	Membrane reconstitution of high-affinity .alpha.2-adrenergic agonist binding with guanine nucleotide regulatory proteins. Biochemistry, 1987, 26, 3664-3672.	2.5	56
257	Large-scale purification of Î±2-adrenergic receptor-enriched membranes from human platelets. Persistent association of guanine nucleotides with nonpurified membranes. Biochimica Et Biophysica Acta - Biomembranes, 1986, 854, 67-76.	2.6	18
258	Guanine nucleotide effects on catecholamine secretion from digitonin-permeabilized adrenal chromaffin cells.. Journal of Biological Chemistry, 1986, 261, 10182-10188.	3.4	120
259	Guanine nucleotide effects on catecholamine secretion from digitonin-permeabilized adrenal chromaffin cells. Journal of Biological Chemistry, 1986, 261, 10182-8.	3.4	101
260	Pharmacologic reduction of sympathetic drive increases platelet alpha-2â€“receptor number. Clinical Pharmacology and Therapeutics, 1985, 38, 519-524.	4.7	21
261	Parallel inactivation of Î±2 -adrenergic agonist binding and Ni by alkaline treatment. FEBS Letters, 1985, 192, 321-325.	2.8	21
262	Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry. Molecular Pharmacology, 1985, 28, 475-86.	2.3	57
263	Conformations of Torpedo acetylcholine receptor associated with ion transport and desensitization. Biochemistry, 1982, 21, 3460-3467.	2.5	141
264	Immunofluorescence localization at the mammalian neuromuscular junction of the Mr 43,000 protein of Torpedo postsynaptic membranes.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 5230-5234.	7.1	140
265	Acetylcholine and local anesthetic binding to Torpedo nicotinic postsynaptic membranes after removal of nonreceptor peptides.. Proceedings of the National Academy of Sciences of the United States of America, 1979, 76, 690-694.	7.1	352